Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$4.4M
Program Spending
84%
of total expenses go to program services
Total Contributions
$2.6M
Total Expenses
▼$4.1M
Total Assets
$5.4M
Total Liabilities
▼$792K
Net Assets
$4.6M
Officer Compensation
→$196.3K
Other Salaries
$1.4M
Investment Income
$158.4K
Fundraising
▼N/A
Tax Year 2024 · Source: IRS Form 990, Schedule I (Grants and Other Assistance)
Total grants awarded: $550K
| Recipient | Location | Amount | Type | Purpose |
|---|---|---|---|---|
PORTLAND STATE UNIVERSITY36-4776757 | PORTLAND, OR | $264.5K | Cash | RESEARCH |
| MINNEAPOLIS, MN | $110.5K | Cash | RESEARCH | |
STANFORD UNIVERSITY94-1156365 | LOS ANGELES, CA | $48.5K | Cash | RESEARCH |
DVARC75-2329831 | DALLAS, TX | $45K | Cash | RESEARCH |
SYRACUSE UNIVERSITY15-0532081 | SYRACUSE, NY | $37.3K | Cash | RESEARCH |
THE PENNSYLVANIA STATE UNIVERSITY24-6000376 | UNIVERSITY PARK, PA | $32.6K | Cash | RESEARCH |
OREGON HEALTH & SCIENCE UNIVERSITY93-1176109 | PORTLAND, OR | $11.5K | Cash | RESEARCH |
| Total | $550K | |||
PORTLAND, OR
$264.5K
MINNEAPOLIS, MN
$110.5K
LOS ANGELES, CA
$48.5K
DALLAS, TX
$45K
SYRACUSE, NY
$37.3K
UNIVERSITY PARK, PA
$32.6K
PORTLAND, OR
$11.5K
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$31.2K
VA/DoD Award Count
2
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$9.4M
Awards Found
9
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | ASSESSMENT OF ANOMIA: IMPROVING EFFICIENCY AND UTILITY USING ITEM RESPONSE THEORY | $2.9M | FY2020 | Sep 2020 – Aug 2026 |
| Department of Health and Human Services | OPTIMIZING AND UNDERSTANDING SEMANTIC FEATURE ANALYSIS TREATMENT FOR APHASIA: A RANDOMIZED CONTROLLED COMPARATIVE-EFFECTIVENESS TRIAL | $2.6M | FY2019 | Sep 2019 – Aug 2026 |
| Department of Health and Human Services | EAVESDROPPING ON HEART-BRAIN CONVERSATIONS DURING SLEEP FOR EARLY DETECTION AND PREVENTION OF FATAL CARDIOVASCULAR DISEASE | $2.4M | FY2020 | Aug 2020 – Jun 2025 |
| Department of Health and Human Services | RESEARCH SYMPOSIUM IN CLINICAL APHASIOLOGY | $561.6K | FY2003 | May 2003 – Aug 2027 |
| Department of Health and Human Services | IMPACT OF FOOD-DERIVED POLYPHENOLS ON DOPAMINE NEURONS IN THE AGED BRAIN | $348.5K | FY2018 | Aug 2018 – Jul 2021 |
| Department of Health and Human Services | ORAL ANTIVIRALS AGAINST COVID-19 AND CLINICAL OUTCOMES IN HIGH RISK POPULATIONS - COVID-19 HAS LED TO OVER 350 MILLION REPORTED CASES AND OVER 5.6 MILLION RESULTING DEATHS GLOBALLY, AND NEARLY 72 MILLION CASES AND >900,000 DEATHS IN THE US. HIGHLY EFFECTIVE VACCINES ARE NOW AVAILABLE AND ARE THE FIRST LINE OF DEFENSE. HOWEVER, IMMUNITY WANES OFF OVER TIME AND BREAKTHROUGH INFECTIONS IN FULLY VACCINATED PERSONS HAVE BEEN REPORTED, PARTICULARLY WITH THE NEWER VARIANTS. IN DECEMBER 2021, TWO NOVEL ORAL ANTIVIRAL AGENTS, NIRMATRELVIR/RITONAVIR (NMV/R) AND MOLNUPIRAVIR (MPV), WERE GRANTED EMERGENCY USE AUTHORIZATION (EUA) BY THE FDA FOR TREATMENT OF EARLY SYMPTOMATIC PATIENTS WITH MILD TO MODERATE COVID-19 AT HIGH RISK OF PROGRESSION TO SEVERE DISEASE. THESE AUTHORIZATIONS WERE GRANTED BASED ON LIMITED PUBLISHED DATA, AND CRITICAL QUESTIONS ABOUT THEIR COMPARATIVE EFFECTIVENESS, EFFECTIVENESS IN THE REAL-WORLD SETTINGS, AND EFFECTIVENESS IN SPECIFIC HIGH-RISK SUB-POPULATIONS REMAIN TO BE ANSWERED. THERE IS AN URGENT NEED TO UNDERSTAND THE REAL-WORLD EFFECTIVENESS OF THESE DRUGS, ESPECIALLY IN THE HIGH-RISK AND VULNERABLE POPULATIONS, AS WELL AS LONGER TERM CLINICAL OUTCOMES IN TREATED PATIENTS. SUCH KNOWLEDGE IS ESSENTIAL FOR THE PATIENTS, PROVIDERS, PAYORS, AND POLICYMAKERS, TO ENSURE THAT THEY ARE USED ONLY IN THE APPROPRIATE POPULATIONS AND SITUATIONS BASED ON STRONG CLINICAL EVIDENCE. TO ADDRESS THESE CRITICAL GAPS IN KNOWLEDGE, WE PROPOSE THE FOLLOWING HYPOTHESES: HYPOTHESIS 1: TREATMENT WITH NMV/R OR MPV WILL BE ASSOCIATED WITH A SIGNIFICANT REDUCTION IN COVID-19 RELATED HOSPITALIZATION AND 30-DAY ALL-CAUSE MORTALITY IN OLDER PERSONS, THOSE WITH A HIGH COMORBIDITY BURDEN, AND IN SOCIALLY VULNERABLE PERSONS. HYPOTHESIS 2: WE HYPOTHESIZE THAT NMV/R AND MPV TREATMENT WILL BE ASSOCIATED WITH A SIGNIFICANT REDUCTION IN SUBSEQUENT HOSPITAL ADMISSIONS, EMERGENCY DEPARTMENT VISITS, AND OUTPATIENT CLINIC VISITS OVER A 1-YEAR PERIOD AFTER RECOVERY. TREATMENT WILL ALSO BE ASSOCIATED WITH A LOWER INCIDENCE OF ACUTE MYOCARDIAL INFARCTION, STROKE, DECLINE IN RENAL FUNCTION, AND DIABETES, COMPARED WITH PROPENSITY-SCORE MATCHED UNTREATED PERSONS. WE WILL USE THE DEPARTMENT OF VETERANS AFFAIRS’ COVID-19 SHARED DATA RESOURCE (VA ORDCOVID) WHICH CONTAINS EXTENSIVE DEMOGRAPHIC, CLINICAL, PHARMACOLOGIC, LABORATORY, VITAL SIGNS AND CLINICAL OUTCOMES INFORMATION DERIVED FROM MULTIPLE VALIDATED SOURCES. WE WILL COMPARE THOSE TREATED WITH NMV/R OR MPV WITH PROPENSITY-SCORE MATCHED UNTREATED CONTROLS, MATCHED ON DEMOGRAPHICS, CLINICAL VARIABLES, SEVERITY OF PRESENTING ILLNESS, GEOGRAPHIC LOCATION, TIME OF TREATMENT, VACCINATION STATUS, TIME FROM COMPLETION OF A FULL COURSE OF VACCINATION, AND BOOSTER DOSE ADMINISTRATION. THE PI, DR. BUTT HAS EXTENSIVE EXPERIENCE IN CREATING AND ANALYSING LARGE NATIONAL DATABASES AND HAS PUBLISHED 45 PAPERS ON COVID-19 IN JOURNALS INCLUDING THE NEW ENGLAND JOURNAL OF MEDICINE, ANNALS OF INTERNAL MEDICINE, JAMA INTERNAL MEDICINE, JOURNAL OF CLINICAL INVESTIGATION, NATURE MEDICINE, AND OTHERS. HE ALREADY HAS IRB APPROVAL TO STUDY THE EPIDEMIOLOGY, NATURAL HISTORY, AND CLINICAL OUTCOMES OF SARS-COV-2 INFECTION IN THE VA POPULATION. | $347.2K | FY2023 | Jul 2023 – Jun 2026 |
| Department of Health and Human Services | ELDER ABUSE PREVENTION INTERVENTIONS PROGRAM - THE VETERANS HEALTH FOUNDATION (VHF), IN PARTNERSHIP WITH THE VA PITTSBURGH AND VA BUTLER HEALTHCARE SYSTEMS AND PENNSYLVANIA AREA AGENCIES ON AGING IN ALLEGHENY AND BUTLER COUNTIES WILL, OVER THIS THREE-YEAR PROJECT, DEVELOP AND PILOT AN ELDER MISTREATMENT (EM) INTERVENTION PROGRAM CALLED THRIVE (TRANSFORMING HEALTH AND RESILIENCE IN VETERANS) IN THE VETERANS HEALTH ADMINISTRATION TO IMPROVE OUTCOMES FOR THE NEARLY 5 MILLION OLDER VETERANS IT SERVES. THE GOALS OF THIS PROJECT ARE: 1) ESTABLISH A NEW MODEL FOR PARTNERSHIP BETWEEN COUNTY ADULT PROTECTIVE SERVICES (APS) AGENCIES AND LOCAL VA MEDICAL CENTERS (VAMCS), AND 2) DEVELOP, REFINE AND CONDUCT A FEASIBILITY PILOT OF THE THRIVE INTERVENTION. THE OBJECTIVES ARE: 1) CREATE A LOCAL VAMC-APS ADVISORY WORKGROUP WITH KEY STAKEHOLDERS FROM THE PITTSBURGH AND BUTLER VAMCS AND APS AGENCIES TO DEVELOP STANDARD OPERATING PROCEDURES FOR EM CASE COLLABORATION; 2) CONDUCT STAKEHOLDER-ENGAGED THRIVE REFINEMENT AND PRE-IMPLEMENTATION ASSESSMENT TO INTEGRATE THRIVE AT THE PITTSBURGH AND BUTLER VAMCS; 3) DEVELOP AND TEST THRIVE TRAINING MATERIALS AND 4) PILOT TEST THRIVE AT VA PITTSBURGH AND VA BUTLER TO ASSESS FEASIBILITY, ACCEPTABILITY, AND PRELIMINARY EFFECTIVENESS. ANTICIPATED OUTCOMES INCLUDE: 1) IMPROVED SATISFACTION AND PERCEIVED BENEFITS ON QUALITY OF LIFE FOR OLDER VETERANS RECEIVING THRIVE AND 2) SATISFACTION WITH THRIVE AND IMPROVEMENT IN SERVICE DELIVERY FOR APS AND VAMC STAFF. EXPECTED PRODUCTS ARE: 1) ONE VA-FACING AND ONE APS-FACING PLAYBOOK FOR HOW TO DEVELOP A VAMC-APS PARTNERSHIP TO PROMOTE NATIONAL REPLICATION OF THESE PARTNERSHIPS; 2) PRELIMINARY THRIVE PLAYBOOK THAT FOR DISSEMINATION WITHIN VHA TO ENHANCE USUAL CARE; 3) MATERIALS FOR A LARGER TRIAL OF THRIVE TO BUILD THE EVIDENCE BASE FOR THIS PROGRAM. | $231.6K | FY2025 | Sep 2025 – Sep 2028 |
| VA/DoDDepartment of Defense | INCIDENCE OF UPPER EXTREMITY NERVE ENTRAPMENTS IN VETERANS WITH MAJOR LIMP AMPUTATIONS | $16.8K | FY2008 | Mar 2008 – Mar 2009 |
| VA/DoDDepartment of Defense | HELPING SEVERELY INJURED SOLDIERS PARTICIPATE FULLY IN SOCIETY | $14.3K | FY2008 | Mar 2008 – Mar 2009 |
Department of Health and Human Services
$2.9M
ASSESSMENT OF ANOMIA: IMPROVING EFFICIENCY AND UTILITY USING ITEM RESPONSE THEORY
Department of Health and Human Services
$2.6M
OPTIMIZING AND UNDERSTANDING SEMANTIC FEATURE ANALYSIS TREATMENT FOR APHASIA: A RANDOMIZED CONTROLLED COMPARATIVE-EFFECTIVENESS TRIAL
Department of Health and Human Services
$2.4M
EAVESDROPPING ON HEART-BRAIN CONVERSATIONS DURING SLEEP FOR EARLY DETECTION AND PREVENTION OF FATAL CARDIOVASCULAR DISEASE
Department of Health and Human Services
$561.6K
RESEARCH SYMPOSIUM IN CLINICAL APHASIOLOGY
Department of Health and Human Services
$348.5K
IMPACT OF FOOD-DERIVED POLYPHENOLS ON DOPAMINE NEURONS IN THE AGED BRAIN
Department of Health and Human Services
$347.2K
ORAL ANTIVIRALS AGAINST COVID-19 AND CLINICAL OUTCOMES IN HIGH RISK POPULATIONS - COVID-19 HAS LED TO OVER 350 MILLION REPORTED CASES AND OVER 5.6 MILLION RESULTING DEATHS GLOBALLY, AND NEARLY 72 MILLION CASES AND >900,000 DEATHS IN THE US. HIGHLY EFFECTIVE VACCINES ARE NOW AVAILABLE AND ARE THE FIRST LINE OF DEFENSE. HOWEVER, IMMUNITY WANES OFF OVER TIME AND BREAKTHROUGH INFECTIONS IN FULLY VACCINATED PERSONS HAVE BEEN REPORTED, PARTICULARLY WITH THE NEWER VARIANTS. IN DECEMBER 2021, TWO NOVEL ORAL ANTIVIRAL AGENTS, NIRMATRELVIR/RITONAVIR (NMV/R) AND MOLNUPIRAVIR (MPV), WERE GRANTED EMERGENCY USE AUTHORIZATION (EUA) BY THE FDA FOR TREATMENT OF EARLY SYMPTOMATIC PATIENTS WITH MILD TO MODERATE COVID-19 AT HIGH RISK OF PROGRESSION TO SEVERE DISEASE. THESE AUTHORIZATIONS WERE GRANTED BASED ON LIMITED PUBLISHED DATA, AND CRITICAL QUESTIONS ABOUT THEIR COMPARATIVE EFFECTIVENESS, EFFECTIVENESS IN THE REAL-WORLD SETTINGS, AND EFFECTIVENESS IN SPECIFIC HIGH-RISK SUB-POPULATIONS REMAIN TO BE ANSWERED. THERE IS AN URGENT NEED TO UNDERSTAND THE REAL-WORLD EFFECTIVENESS OF THESE DRUGS, ESPECIALLY IN THE HIGH-RISK AND VULNERABLE POPULATIONS, AS WELL AS LONGER TERM CLINICAL OUTCOMES IN TREATED PATIENTS. SUCH KNOWLEDGE IS ESSENTIAL FOR THE PATIENTS, PROVIDERS, PAYORS, AND POLICYMAKERS, TO ENSURE THAT THEY ARE USED ONLY IN THE APPROPRIATE POPULATIONS AND SITUATIONS BASED ON STRONG CLINICAL EVIDENCE. TO ADDRESS THESE CRITICAL GAPS IN KNOWLEDGE, WE PROPOSE THE FOLLOWING HYPOTHESES: HYPOTHESIS 1: TREATMENT WITH NMV/R OR MPV WILL BE ASSOCIATED WITH A SIGNIFICANT REDUCTION IN COVID-19 RELATED HOSPITALIZATION AND 30-DAY ALL-CAUSE MORTALITY IN OLDER PERSONS, THOSE WITH A HIGH COMORBIDITY BURDEN, AND IN SOCIALLY VULNERABLE PERSONS. HYPOTHESIS 2: WE HYPOTHESIZE THAT NMV/R AND MPV TREATMENT WILL BE ASSOCIATED WITH A SIGNIFICANT REDUCTION IN SUBSEQUENT HOSPITAL ADMISSIONS, EMERGENCY DEPARTMENT VISITS, AND OUTPATIENT CLINIC VISITS OVER A 1-YEAR PERIOD AFTER RECOVERY. TREATMENT WILL ALSO BE ASSOCIATED WITH A LOWER INCIDENCE OF ACUTE MYOCARDIAL INFARCTION, STROKE, DECLINE IN RENAL FUNCTION, AND DIABETES, COMPARED WITH PROPENSITY-SCORE MATCHED UNTREATED PERSONS. WE WILL USE THE DEPARTMENT OF VETERANS AFFAIRS’ COVID-19 SHARED DATA RESOURCE (VA ORDCOVID) WHICH CONTAINS EXTENSIVE DEMOGRAPHIC, CLINICAL, PHARMACOLOGIC, LABORATORY, VITAL SIGNS AND CLINICAL OUTCOMES INFORMATION DERIVED FROM MULTIPLE VALIDATED SOURCES. WE WILL COMPARE THOSE TREATED WITH NMV/R OR MPV WITH PROPENSITY-SCORE MATCHED UNTREATED CONTROLS, MATCHED ON DEMOGRAPHICS, CLINICAL VARIABLES, SEVERITY OF PRESENTING ILLNESS, GEOGRAPHIC LOCATION, TIME OF TREATMENT, VACCINATION STATUS, TIME FROM COMPLETION OF A FULL COURSE OF VACCINATION, AND BOOSTER DOSE ADMINISTRATION. THE PI, DR. BUTT HAS EXTENSIVE EXPERIENCE IN CREATING AND ANALYSING LARGE NATIONAL DATABASES AND HAS PUBLISHED 45 PAPERS ON COVID-19 IN JOURNALS INCLUDING THE NEW ENGLAND JOURNAL OF MEDICINE, ANNALS OF INTERNAL MEDICINE, JAMA INTERNAL MEDICINE, JOURNAL OF CLINICAL INVESTIGATION, NATURE MEDICINE, AND OTHERS. HE ALREADY HAS IRB APPROVAL TO STUDY THE EPIDEMIOLOGY, NATURAL HISTORY, AND CLINICAL OUTCOMES OF SARS-COV-2 INFECTION IN THE VA POPULATION.
Department of Health and Human Services
$231.6K
ELDER ABUSE PREVENTION INTERVENTIONS PROGRAM - THE VETERANS HEALTH FOUNDATION (VHF), IN PARTNERSHIP WITH THE VA PITTSBURGH AND VA BUTLER HEALTHCARE SYSTEMS AND PENNSYLVANIA AREA AGENCIES ON AGING IN ALLEGHENY AND BUTLER COUNTIES WILL, OVER THIS THREE-YEAR PROJECT, DEVELOP AND PILOT AN ELDER MISTREATMENT (EM) INTERVENTION PROGRAM CALLED THRIVE (TRANSFORMING HEALTH AND RESILIENCE IN VETERANS) IN THE VETERANS HEALTH ADMINISTRATION TO IMPROVE OUTCOMES FOR THE NEARLY 5 MILLION OLDER VETERANS IT SERVES. THE GOALS OF THIS PROJECT ARE: 1) ESTABLISH A NEW MODEL FOR PARTNERSHIP BETWEEN COUNTY ADULT PROTECTIVE SERVICES (APS) AGENCIES AND LOCAL VA MEDICAL CENTERS (VAMCS), AND 2) DEVELOP, REFINE AND CONDUCT A FEASIBILITY PILOT OF THE THRIVE INTERVENTION. THE OBJECTIVES ARE: 1) CREATE A LOCAL VAMC-APS ADVISORY WORKGROUP WITH KEY STAKEHOLDERS FROM THE PITTSBURGH AND BUTLER VAMCS AND APS AGENCIES TO DEVELOP STANDARD OPERATING PROCEDURES FOR EM CASE COLLABORATION; 2) CONDUCT STAKEHOLDER-ENGAGED THRIVE REFINEMENT AND PRE-IMPLEMENTATION ASSESSMENT TO INTEGRATE THRIVE AT THE PITTSBURGH AND BUTLER VAMCS; 3) DEVELOP AND TEST THRIVE TRAINING MATERIALS AND 4) PILOT TEST THRIVE AT VA PITTSBURGH AND VA BUTLER TO ASSESS FEASIBILITY, ACCEPTABILITY, AND PRELIMINARY EFFECTIVENESS. ANTICIPATED OUTCOMES INCLUDE: 1) IMPROVED SATISFACTION AND PERCEIVED BENEFITS ON QUALITY OF LIFE FOR OLDER VETERANS RECEIVING THRIVE AND 2) SATISFACTION WITH THRIVE AND IMPROVEMENT IN SERVICE DELIVERY FOR APS AND VAMC STAFF. EXPECTED PRODUCTS ARE: 1) ONE VA-FACING AND ONE APS-FACING PLAYBOOK FOR HOW TO DEVELOP A VAMC-APS PARTNERSHIP TO PROMOTE NATIONAL REPLICATION OF THESE PARTNERSHIPS; 2) PRELIMINARY THRIVE PLAYBOOK THAT FOR DISSEMINATION WITHIN VHA TO ENHANCE USUAL CARE; 3) MATERIALS FOR A LARGER TRIAL OF THRIVE TO BUILD THE EVIDENCE BASE FOR THIS PROGRAM.
Department of Defense
$16.8K
INCIDENCE OF UPPER EXTREMITY NERVE ENTRAPMENTS IN VETERANS WITH MAJOR LIMP AMPUTATIONS
Department of Defense
$14.3K
HELPING SEVERELY INJURED SOLDIERS PARTICIPATE FULLY IN SOCIETY
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990Schedule J available
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $4.4M | $2.6M | $4.1M | $5.4M | $4.6M |
| 2023IRS e-File | $3.4M | $2M | $3M | $5.1M | $4.3M |
| 2022 | $2.6M | $1.7M | $2.9M | $4.4M | $3.9M |
| 2021 | $2.5M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Ali Sonel Md | Chairman | 0.4 | $0 | $415.4K | $131.6K | $547K |
| Alanna Caffas | Chief Executive Officer | 40 | $172.3K | $0 | $36.7K | $209K |
| Jennifer Mock | Finance & Operations Manag | 40 | $69.8K | $0 | $30.5K | $100.3K |
| Phil Hahn | Secretary/treasurer | 0.3 | $0 | $0 | $0 | $0 |
Ali Sonel Md
Chairman
$547K
Hrs/Wk
0.4
Compensation
$0
Related Orgs
$415.4K
Other
$131.6K
Alanna Caffas
Chief Executive Officer
$209K
Hrs/Wk
40
Compensation
$172.3K
Related Orgs
$0
Other
$36.7K
Jennifer Mock
Finance & Operations Manag
$100.3K
Hrs/Wk
40
Compensation
$69.8K
Related Orgs
$0
Other
$30.5K
Phil Hahn
Secretary/treasurer
$0
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Adeel Butt | Principal Investigator | 40 | $128.3K | $0 | $16.2K | $144.5K |
Adeel Butt
Principal Investigator
$144.5K
Hrs/Wk
40
Compensation
$128.3K
Related Orgs
$0
Other
$16.2K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Akshar Abbott | Board Member | 0.3 | $0 | $0 | $0 | $0 |
| D James Mcmahon Cpa | Board Member | 0.3 | $0 | $0 | $0 | $0 |
| Donald Koenig Jd | Board Member | 0.3 | $0 | $252.7K | $78.9K | $331.6K |
| Frank Decarlo | Board Member | 0.3 | $0 | $0 | $0 | $0 |
| Lyndsay Tkach | Board Member | 0.3 |
Akshar Abbott
Board Member
$0
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$0
Other
$0
D James Mcmahon Cpa
Board Member
$0
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$0
Other
$0
Donald Koenig Jd
Board Member
$331.6K
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$252.7K
Other
$78.9K
| $1.7M |
| $2.9M |
| $4.9M |
| $4.3M |
| 2020 | $1.9M | $1.1M | $2.1M | $5.5M | $4.8M |
| 2019 | $2M | $87.9K | $2.2M | $5.4M | $5M |
| 2018 | $3.6M | $1.6M | $2M | $5.4M | $5.1M |
| 2017 | $2.3M | $31.4K | $2M | $3.7M | $3.5M |
| 2016 | $2.3M | $1,473 | $2M | $3.5M | $3.3M |
| 2015 | $2M | $26.8K | $1.9M | $3.4M | $3M |
| 2014 | $1.8M | $12.3K | $1.8M | $3.3M | $2.8M |
| 2013 | $2.2M | $13.1K | $2.2M | $3M | $2.9M |
| 2012 | $2.7M | $5,984 | $3M | $3.1M | $3M |
| 2011 | $3.2M | $1,296 | $3.3M | $3.4M | $3.3M |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data | PDF not yet published by IRS |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| $0 |
| $0 |
| $0 |
| $0 |
| Ronald Poropatch Md | Board Member | 0.3 | $0 | $0 | $0 | $0 |
| Russell E Lloyd | Board Member | 0.3 | $0 | $214K | $76K | $290K |
| Sharon Coyle | Board Member | 0.3 | $0 | $186.4K | $0 | $186.4K |
| Walid Gellad | Board Member | 0.4 | $0 | $378.9K | $117.5K | $496.4K |
Frank Decarlo
Board Member
$0
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$0
Other
$0
Lyndsay Tkach
Board Member
$0
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$0
Other
$0
Ronald Poropatch Md
Board Member
$0
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$0
Other
$0
Russell E Lloyd
Board Member
$290K
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$214K
Other
$76K
Sharon Coyle
Board Member
$186.4K
Hrs/Wk
0.3
Compensation
$0
Related Orgs
$186.4K
Other
$0
Walid Gellad
Board Member
$496.4K
Hrs/Wk
0.4
Compensation
$0
Related Orgs
$378.9K
Other
$117.5K